Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05404581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Insula Neuromodulation for Chronic Neuropathic Pain

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Jun 30, 2026 → Jul 1, 2028
See other at-risk trials from University of Virginia

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description shortened, about 4 words
  2. Primary completion pushed from Jun 30, 2026 to Jul 1, 2028
    • Study completion pushed from Jun 29, 2027 to Jul 1, 2028
    • Eligibility criteria expanded, about 43 words
    • Publications: details revised at 1 of 1 entry
  3. Study completion date: Jun 30, 2027 to Jun 29, 2027v5
  4. Phase: Phase 1/2 to Not applicable
    • Eligibility criteria revised
    • Site contact updated
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 1, 2022 to Nov 1, 2022
    • Study sites: 0 to 1
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will comprehensively investigate the insula as a brain target for neuromodulation to treat chronic neuropathic pain.
Trial Details
NCT Number NCT05404581
Lead Sponsor University of Virginia
Collaborators: Boston Scientific Corporation
Conditions
(from sponsor)		 Neuropathic Pain, Chronic Pain
Related terms Chronic Pain, Neuralgia
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov